Berberine chloride (Synonyms: 盐酸小檗碱; Natural Yellow 18 chloride)

目录号: HY-18258 纯度: 99.92%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Berberine chloride 是一种生物碱，常用作抗生素。Berberine chloride 诱导活性氧 (ROS) 生成并抑制 DNA 拓扑异构酶 (topoisomerase)。抗肿瘤特性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Berberine chloride Chemical Structure

CAS No. : 633-65-8

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥429	In-stock
50 mg	￥390	In-stock
100 mg	￥660	In-stock
500 mg	￥1140	In-stock
1 g	￥1600	In-stock
5 g	￥2400	In-stock
10 g	￥2880	In-stock
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Berberine chloride:

MCE 顾客使用本产品发表的 65 篇科研文献

Proliferation Assay

Cell Viability Assay

: Berberine chloride purchased from MCE. Usage Cited in: BMC Pharmacol Toxicol. 2023 May 11;24(1):29. [Abstract]; Berberine (BBR; 2.5, 5, 10 µM; 48 h) inhibits EGFR phosphorylation in a dose-dependent matter in A431cells.

: Berberine chloride purchased from MCE. Usage Cited in: BMC Pharmacol Toxicol. 2023 May 11;24(1):29. [Abstract]; Berberine (BBR; 0.625, 1.25, 2.5, 5, 10 µM; 48 h) inhibits the viability of A431cells in a dose-dependent matter.

: Berberine chloride purchased from MCE. Usage Cited in: BMC Pharmacol Toxicol. 2023 May 11;24(1):29. [Abstract]; Berberine (BBR; 2.5 µM; 10 days) significantly inhibits NCI-H441 colony formation.

Berberine chloride 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Topoisomerase 亚型特异性产品:

查看所有亚型

Topoisomerase Topo I Topo II

查看 Antibiotic 亚型特异性产品:

查看所有亚型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

查看 Parasite 亚型特异性产品:

查看所有亚型

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

生物活性
纯度 & 产品资料
参考文献

生物活性

Berberine chloride is an alkaloid that acts as an antibiotic. Berberine chloride induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties^[1].

IC₅₀ & Target

ROS^[1]
DNA topoisomerase^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A10	GI₅₀	101.62 μM Compound: 2	Growth inhibition against rat A10 cells after 72 hrs by MTT assay Growth inhibition against rat A10 cells after 72 hrs by MTT assay	[PMID: 21401114]
A2780	IC₅₀	> 50 μM Compound: BBR; 1	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
A549	IC₅₀	6.27 μM Compound: 10	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 20594848]
A549	IC₅₀	> 50 μM Compound: BBR	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38086195]
A549	IC₅₀	> 50 μM Compound: BBR; 1	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
BGC-823	IC₅₀	7.04 μM Compound: 1, Berberine	Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay	10.1007/s00044-013-0796-9
Bel-7402	IC₅₀	16.28 μM Compound: 1, Berberine	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay	10.1007/s00044-013-0796-9
C6	IC₅₀	> 20 μM Compound: 1	Cytotoxicity against rat C6 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay Cytotoxicity against rat C6 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay	10.1039/C4MD00264D
CCRF S-180	IC₅₀	25 μM Compound: BBR	Antiproliferative activity against mouse CCRF S-180 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against mouse CCRF S-180 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33848698]
CCRF-CEM	CC₅₀	2.09 μM Compound: 1	Cytotoxicity against human CEM cells expressing green fluorescent protein after 48 hrs by MTT assay Cytotoxicity against human CEM cells expressing green fluorescent protein after 48 hrs by MTT assay	[PMID: 21295891]
CCRF-CEM	EC₅₀	0.13 μM Compound: 1	Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production measured 7 days post infection by ELISA Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production measured 7 days post infection by ELISA	[PMID: 21295891]
CHO-K1	IC₅₀	336 μM Compound: BBR	Cytotoxicity against CHO-K1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against CHO-K1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32688201]
DU-145	IC₅₀	> 20 μM Compound: BBR	Antiproliferative activity against human DU145 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human DU145 cells assessed as cell growth inhibition by SRB assay	[PMID: 31812467]
G-402	GI₅₀	11.87 μM Compound: 2	Growth inhibition against human G402 cells after 48 hrs by MTT assay Growth inhibition against human G402 cells after 48 hrs by MTT assay	[PMID: 21401114]
HCT-116	IC₅₀	25 μM Compound: BBR	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33848698]
HCT-116	IC₅₀	39.95 μM Compound: Berberine Chloride	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28359045]
HCT-116	IC₅₀	83.09 μM Compound: Ber	Inhibition of cell proliferation of human HCT116 cells incubated for 15 hrs by MTT assay Inhibition of cell proliferation of human HCT116 cells incubated for 15 hrs by MTT assay	[PMID: 32391701]
HCT-116	IC₅₀	> 10 μM Compound: BBR	Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition by SRB assay	[PMID: 31812467]
HCT-15	IC₅₀	16.59 μM Compound: 10	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 20594848]
HCT-8	IC₅₀	25 μM Compound: BBR	Antiproliferative activity against human HCT-8 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-8 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33848698]
HL-60	IC₅₀	27.42 μM Compound: Berberine Chloride	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 28359045]
HL-60	IC₅₀	5.83 μM Compound: 1, Berberine	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	10.1007/s00044-013-0796-9
HT-29	IC₅₀	8.45 μM Compound: 1, Berberine	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 23182088]
HT-29	IC₅₀	> 10 μM Compound: BBR	Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition by SRB assay	[PMID: 31812467]
HT-29	IC₅₀	> 20 μM Compound: 1, Berberine	Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay	[PMID: 23182088]
HT-29	IC₅₀	> 50 μM Compound: BBR; 1	Antiproliferative activity against human HT29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
HeLa	IC₅₀	138.4 g/mL Compound: Berberine, I	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 18295494]
HepG2	IC₅₀	11.22 μM Compound: 1, Berberine	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 23182088]
HepG2	IC₅₀	13.8 μM Compound: BER	Down regulation of PCSK9 mRNA expression in human HepG2 cells incubated for 24 hrs by SYBR green dye-based qRT-PCR analysis Down regulation of PCSK9 mRNA expression in human HepG2 cells incubated for 24 hrs by SYBR green dye-based qRT-PCR analysis	[PMID: 33567826]
HepG2	IC₅₀	146.2 g/mL Compound: Berberine, I	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 18295494]
HepG2	IC₅₀	49.01 μM Compound: Berberine Chloride	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 28359045]
HepG2	IC₅₀	53.91 μg/mL Compound: Berberine chloride	Cytotoxicity against human HepG2 cells after 12 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells after 12 hrs by CCK-8 assay	[PMID: 31057739]
HepG2	IC₅₀	8.32 μM Compound: 1, Berberine	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23182088]
HepG2	IC₅₀	> 50 μM Compound: BBR	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38086195]
HepG2	IC₅₀	> 50 μM Compound: BBR; 1	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
Hepatocyte	IC₅₀	26.5 μg/mL Compound: Berberine, I	Cytotoxicity against Sprague-Dawley rat primary hepatocytes after 24 hrs by MTT assay Cytotoxicity against Sprague-Dawley rat primary hepatocytes after 24 hrs by MTT assay	[PMID: 18295494]
Huh-7	CC₅₀	> 100 μM Compound: GNF-Pf-4545	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]
KB	IC₅₀	6.03 μM Compound: 1, Berberine	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	10.1007/s00044-013-0796-9
KB	IC₅₀	7.32 μM Compound: Berberine chloride	Cytotoxicity against human KB cells after 72 hrs Cytotoxicity against human KB cells after 72 hrs	[PMID: 11141105]
KM12C	IC₅₀	76.34 μM Compound: Ber	Inhibition of cell proliferation of human KM12C cells incubated for 15 hrs by MTT assay Inhibition of cell proliferation of human KM12C cells incubated for 15 hrs by MTT assay	[PMID: 32391701]
L02	IC₅₀	71.55 μM Compound: Berberine Chloride	Cytotoxicity against human LO2 cells after 72 hrs by MTT assay Cytotoxicity against human LO2 cells after 72 hrs by MTT assay	[PMID: 28359045]
L02	IC₅₀	> 50 μM Compound: BBR	Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38086195]
L02	IC₅₀	> 50 μM Compound: BBR; 1	Antiproliferative activity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
LNCaP	IC₅₀	> 50 μM Compound: Berberine chloride	Antiproliferative activity against human LNCaP cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human LNCaP cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38215590]
LS174T	IC₅₀	25 μM Compound: BBR	Antiproliferative activity against human LS174T cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human LS174T cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33848698]
MCF-10A	IC₅₀	> 50 μM Compound: Berberine chloride	Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38215590]
MCF7	IC₅₀	75 μM Compound: berberine	Inhibition of telomerase expressed in MCF7 cells by TRAP assay Inhibition of telomerase expressed in MCF7 cells by TRAP assay	[PMID: 17574421]
MCF7	IC₅₀	> 50 μM Compound: Berberine chloride	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38215590]
MDA-MB-231	IC₅₀	20.6 μM Compound: BBR	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by SRB assay	[PMID: 31812467]
MKN-28	IC₅₀	25 μM Compound: BBR	Antiproliferative activity against human MKN-28 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human MKN-28 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33848698]
MRC5	CC₅₀	74 μM Compound: 1	Cytotoxicity against MRC5 cells Cytotoxicity against MRC5 cells	[PMID: 17239594]
MRC5	IC₅₀	0.68 μM Compound: 1	Antiviral activity against HCMV in MRC5 cells by plaque reduction assay Antiviral activity against HCMV in MRC5 cells by plaque reduction assay	[PMID: 17239594]
NCI-H446	IC₅₀	> 50 μM Compound: BBR	Antiproliferative activity against human NCI-H446 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human NCI-H446 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38086195]
PANC-1	IC₅₀	> 50 μM Compound: BBR; 1	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
PANC-1	IC₅₀	> 50 μM Compound: Berberine chloride	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38215590]
PC-12	CC₅₀	> 150 μM Compound: 1	Cytotoxicity against rat PC12 cells assessed as reduction in cell viability incubated for 24 hrs by WST-8 assay Cytotoxicity against rat PC12 cells assessed as reduction in cell viability incubated for 24 hrs by WST-8 assay	[PMID: 33611188]
PC-3	IC₅₀	14.39 μM Compound: BBR	Antiproliferative activity against human PC3 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human PC3 cells assessed as cell growth inhibition by SRB assay	[PMID: 31812467]
PC-3	IC₅₀	31.72 μM Compound: BBR; 1	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
SGC-7901	IC₅₀	25 μM Compound: BBR	Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33848698]
SK-MEL-2	IC₅₀	13.76 μM Compound: 10	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 20594848]
SK-OV-3	IC₅₀	16.44 μM Compound: 10	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 20594848]
SMMC-7721	IC₅₀	25.94 μM Compound: Berberine Chloride	Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 28359045]
SW-620	IC₅₀	126.2 μM Compound: Ber	Inhibition of cell proliferation of human SW620 cells incubated for 15 hrs by MTT assay Inhibition of cell proliferation of human SW620 cells incubated for 15 hrs by MTT assay	[PMID: 32391701]
SW-620	IC₅₀	25 μM Compound: BBR	Antiproliferative activity against human SW620 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 33848698]
THP-1	IC₅₀	5.1 μM Compound: BBR	Inhibition of LPS + nigericin-induced IL-1beta secretion in PMA-differentiated human THP-1 cells incubated for 1 to 24 hrs by Immunoblot analysis Inhibition of LPS + nigericin-induced IL-1beta secretion in PMA-differentiated human THP-1 cells incubated for 1 to 24 hrs by Immunoblot analysis	[PMID: 33440945]
U-87MG ATCC	IC₅₀	> 20 μM Compound: 1	Cytotoxicity against human U87 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay Cytotoxicity against human U87 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay	10.1039/C4MD00264D
U-937	IC₅₀	35 μM Compound: Berberine chloride	Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	10.1039/C0MD00241K
VSMC	GI₅₀	95.1 μM Compound: 2	Antiproliferative activity against rat VSMC assessed as cell growth inhibition Antiproliferative activity against rat VSMC assessed as cell growth inhibition	[PMID: 21401114]
VSMC	GI₅₀	95.14 μM Compound: 2	Growth inhibition against rat VSMC after 72 hrs by MTT assay Growth inhibition against rat VSMC after 72 hrs by MTT assay	[PMID: 21401114]

体外研究
(In Vitro)

Berberine (1.25-160 μM；72 hours) 对四种结直肠癌细胞系 LoVo、HCT116、SW480 和 HT-29 的增殖具有潜在的抑制作用^[1]。
Berberine (1.25-160 μM；24-72 小时) 诱导 LoVo 细胞生长的时间和剂量依赖性抑制^[1]。
LoVo 细胞暴露于小檗碱 (10 -80 μM) 24 小时。通过流式细胞术对 40 μM 小檗碱处理的 LoVo 细胞进行细胞周期分析显示细胞在 G2/M 期积累^[1]。
Berberine (10 -80 μM) 抑制细胞周期蛋白 B1，24 h 后 cdc2 和 cdc25c 蛋白表达，尤其是在80.0 μM 剂量下^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	Four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29
Concentration:	1.25, 2.5, 5, 10, 20, 40, 80, and 160 μM
Incubation Time:	72 hours
Result:	Inhibited the proliferation of four cell lines. The IC₅₀ ranged from 40.8±4.1 μM (LoVo) to 98.6±2.9 μM (HCT116).

Cell Proliferation Assay^[1]

Cell Line:	Colorectal carcinoma cell lines LoVo
Concentration:	1.25, 2.5, 5, 10, 20, 40, 80, and 160 μM
Incubation Time:	24, 48, 72 hours
Result:	Induced a time- and dose-dependent inhibition of cell growth. By 72 h, 160.0 μM induced 71.1±1.9 % growth inhibitions in LoVo cells.

Cell Cycle Analysis^[1]

Cell Line:	LoVo cells
Concentration:	0, 10, 20, 40, or 80 μM
Incubation Time:	24 hours
Result:	Exposure to 40.0 μM induced G2/M-phase cell cycle arrest, an increase in the G2/M-phase population and a progressive decline in the G1 population.

Western Blot Analysis^[1]

Cell Line:	LoVo cells
Concentration:	10, 20, 40, or 80 μM
Incubation Time:	24 hours
Result:	Suppressed cyclin B1, cdc2 and cdc25c protein expression.

体内研究
(In Vivo)

Berberine (10、30 或 50 mg/kg/天；胃肠道强饲法；连续 10 天) 在体内抑制人结直肠腺癌的生长。胃肠道灌胃剂量为 30 和 50 mg/kg/day 的小檗碱对人结直肠腺癌裸鼠异种移植物生长的抑制率分别为 33.1% 和 45.3%^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5-week-old BALB/c nu/nu mice with human colorectal adenocarcinoma LoVo xenografts^[1]
Dosage:	10, 30, or 50 mg/kg/day
Administration:	Gastrointestinal gavage; for 10 consecutive days
Result:	Showed inhibitory rates of 33.1 % and 45.3 % at doses of 30 and 50 mg/kg/day.

Clinical Trial

分子量

371.81

Formula

C₂₀H₁₈ClNO₄

CAS 号

633-65-8

性状

固体

颜色

Light yellow to yellow

中文名称

盐酸小檗碱；盐酸黄连素；盐酸黄莲素

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 8.33 mg/mL (22.40 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6895 mL	13.4477 mL	26.8955 mL
5 mM	0.5379 mL	2.6895 mL	5.3791 mL
10 mM	0.2690 mL	1.3448 mL	2.6895 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (3.36 mM); 澄清溶液

此方案可获得 ≥ 1.25 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (3.36 mM); 澄清溶液

此方案可获得 ≥ 1.25 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 0.5% CMC-Na/saline water
Solubility: 11 mg/mL (29.59 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.92%

选择批次：

Data Sheet (649 KB) SDS (393 KB)

COA (289 KB) RP-HPLC (218 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Cai Y, et al. Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. J Nat Med. 2014 Jan;68(1):53-62. [Content Brief]

Berberine chloride 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6895 mL	13.4477 mL	26.8955 mL	67.2386 mL
	5 mM	0.5379 mL	2.6895 mL	5.3791 mL	13.4477 mL
	10 mM	0.2690 mL	1.3448 mL	2.6895 mL	6.7239 mL
	15 mM	0.1793 mL	0.8965 mL	1.7930 mL	4.4826 mL
	20 mM	0.1345 mL	0.6724 mL	1.3448 mL	3.3619 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Berberine633-65-8Natural Yellow 18盐酸小檗碱盐酸黄连素盐酸黄莲素Natural Yellow18Natural Yellow-18TopoisomeraseAutophagyBacterialReactive Oxygen Species (ROS)AntibioticEndogenous MetaboliteParasiteInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Berberine chloride (Synonyms: 盐酸小檗碱; Natural Yellow 18 chloride)

Customer Review

Other Forms of Berberine chloride:

MCE 顾客使用本产品发表的 65 篇科研文献

Berberine chloride 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Topoisomerase 亚型特异性产品:

查看 Antibiotic 亚型特异性产品:

查看 Parasite 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Berberine chloride 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Berberine chloride (Synonyms: 盐酸小檗碱; Natural Yellow 18 chloride)

Customer Review

Other Forms of Berberine chloride:

Berberine chloride 相关抗体

MCE 顾客使用本产品发表的 65 篇科研文献

Berberine chloride 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Topoisomerase 亚型特异性产品:

查看 Antibiotic 亚型特异性产品:

查看 Parasite 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Berberine chloride 相关抗体:

摩尔计算器

稀释计算器

Berberine chloride 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z